Pacific Edge Limited, a cancer diagnostic company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, Australia, and Singapore. The company operates in two segments, Commercial and Research. It offers Cxbladder, a genomic urine tests for the detection and management of bladder cancer. The company is also developing Cxbladder Resolve, a product that identifies those patients who are likely to have aggressive or more advanced bladder cancer; Cxbladder Triage, a product that identifies patients with haematuria who have a low probability of bladder cancer; Cxbladder Detect that enables the non-invasive detection of bladder and other urinary tract cancers; and Cxbladder Monitor, which allows urologists to monitor bladder cancer patients for recurrence of the disease. In addition, it is developing products for bladder, gastric, colorectal, endometrial cancers, and melanoma. The company was incorporated in 2001 and is headquartered in Dunedin, New Zealand.
| Market Capitalization | $74.5536 million |
| P/E Ratio | 0 |
| P/E Growth Ratio | |
| Book Value | 0.102 |
| Dividend Per Share | 0 |
| Earnings Per Share | -0.03 |
| EBITDA | -31,461 |
| Profit Margin | -1.282 |
| Operating Margin TTM | -1.5241 |
| Return on Assets TTM | -0.1943 |
| Return on Equity TTM | -0.2822 |
| Revenue TTM | 21,033 |
All numbers are in thousands
| Date | Total Revenue | Cost of Revenue | Gross Profit | Total Operating Expenses |
|---|---|---|---|---|
| 2017-03-31 | 3,208 | |||
| 2018-03-31 | 3,400 | |||
| 2019-03-31 | 3,817 | 3,817 | ||
| 2020-03-31 | 4,370 | 4,370 | 24,206 | |
| 2021-03-31 | 2,152 | 2,152 | 24,718 | |
| 2022-03-31 | 11,445 | 11,445 | 33,631 | |
| 2023-03-31 | 19,616 | 19,616 | 54,030 |
All numbers are in thousands
| Date | Cash | Total Assets | Total Liabilities | Short Term Debt | Long Term Debt | Common Stock |
|---|---|---|---|---|---|---|
| 2017-03-31 | 6,564 | 17,707 | 2,734 | 111,596 | ||
| 2018-03-31 | 5,242 | 19,665 | 3,025 | 131,824 | ||
| 2019-03-31 | 4,847 | 16,566 | 2,656 | 146,403 | ||
| 2020-03-31 | 1,755 | 19,328 | 4,824 | 983 | 165,423 | |
| 2021-03-31 | 4,129 | 31,184 | 6,075 | 1,098 | 190,305 | |
| 2022-03-31 | 105,412 | 124,025.82033 | 7,429.800969999999 | 1,072 | 294,139 | |
| 2023-03-31 | 77,791 | 97,118.89755 | 8,706.334789999999 | 811 | 294,317 |
All numbers are in thousands
| Date | Net Income | Total Cash | Change in Cash | Begin period cash | End period cash | Dividends |
|---|---|---|---|---|---|---|
| 2017-03-31 | -17,837.4 | 2,403.61 | ||||
| 2018-03-31 | -18,100 | -1,322 | 5,242 | |||
| 2019-03-31 | -17,918 | -17,507 | -395 | 5,242 | 4,847 | |
| 2020-03-31 | -18,886 | -15,385 | -3,092 | 4,847 | 1,755 | |
| 2021-03-31 | -14,223 | -13,570 | 2,374 | 1,755 | 4,129 | |
| 2022-03-31 | -19,788 | 31,283 | 4,129 | 35,412 | ||
| 2023-03-31 | -26,965 | -2,183 | 35,412 | 33,229 |